Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial

Autor: Monica Lorusso, Arrigo Barabino, Stefania Manenti, Salvatore Pellegrino, Vincenzo Villanacci, Giuseppe Maggiore, F. Mangiantini, Marcella Montico, Massimo Maschio, Alessandro Ventura, Rossella Paparazzo, G. Palla, Matteo Bramuzzo, Paolo Lionetti, Giovanna Zuin, Giuseppe Magazzù, Marzia Lazzerini, Sara De Iudicibus, Maria Chiara Pellegrin, Stefano Martelossi, Massimo Fontana, Maria Cristina Lucanto, Giuliana Decorti, A. Calvi, Serena Arrigo
Přispěvatelé: Lazzerini, M, Martelossi, S, Magazzù, G, Pellegrino, S, Lucanto, Mc, Barabino, A, Calvi, A, Arrigo, S, Lionetti, P, Lorusso, M, Mangiantini, F, Fontana, M, Zuin, G, Palla, G, Maggiore, G, Bramuzzo, M, Pellegrin, Mc, Maschio, M, Villanacci, V, Manenti, S, Decorti, Giuliana, DE IUDICIBUS, Sara, Paparazzo, R, Montico, M, Ventura, Alessandro
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Popis: Importance Pediatric-onset Crohn disease is more aggressive than adult-onset disease, has high rates of resistance to existing drugs, and can lead to permanent impairments. Few trials have evaluated new drugs for refractory Crohn disease in children. Objective To determine whether thalidomide is effective in inducing remission in refractory pediatric Crohn disease. Design, Setting, and Patients Multicenter, double-blind, placebo-controlled, randomized clinical trial of 56 children with active Crohn disease despite immunosuppressive treatment, conducted August 2008�September 2012 in 6 pediatric tertiary care centers in Italy. Interventions Thalidomide, 1.5 to 2.5 mg/kg per day, or placebo once daily for 8 weeks. In an open-label extension, nonresponders to placebo received thalidomide for an additional 8 weeks. All responders continued to receive thalidomide for an additional minimum 52 weeks. Main Outcomes and Measures Primary outcomes were clinical remission at week 8, measured by Pediatric Crohn Disease Activity Index (PCDAI) score and reduction in PCDAI by ?25% or ?75% at weeks 4 and 8. Primary outcomes during the open-label follow-up were clinical remission and 75% response. Results Twenty-eight children were randomized to thalidomide and 26 to placebo. Clinical remission was achieved by significantly more children treated with thalidomide (13/28 [46.4%] vs 3/26 [11.5%]; risk ratio [RR], 4.0 [95% CI, 1.2-12.5]; P = .01; number needed to treat [NNT], 2.86). Responses were not different at 4 weeks, but greater improvement was observed at 8 weeks in the thalidomide group (75% response, 13/28 [46.4%] vs 3/26 [11.5%]; RR, 4.0 [95% CI, 1.2-12.5]; NNT = 2.86; P = .01; and 25% response, 18/28 [64.2%] vs 8/26 [30.8%]; RR, 2.1 [95% CI, 1.1-3.9]; NNT = 2.99; P = .01). Of the nonresponders to placebo who began receiving thalidomide, 11 of 21 (52.4%) subsequently reached remission at week 8 (RR, 4.5 [95% CI, 1.4-14.1]; NNT = 2.45; P = .01). Overall, 31 of 49 children treated with thalidomide (63.3%) achieved clinical remission, and 32 of 49 (65.3%) achieved 75% response. Mean duration of clinical remission in the thalidomide group was 181.1 weeks (95% CI, 144.53-217.76) vs 6.3 weeks (95% CI, 3.51-9.15) in the placebo group (P < .001). Cumulative incidence of severe adverse events was 2.1 per 1000 patient-weeks, with peripheral neuropathy the most frequent severe adverse event. Conclusions and Relevance In children and adolescents with refractory Crohn disease, thalidomide compared with placebo resulted in improved clinical remission at 8 weeks of treatment and longer-term maintenance of remission in an open-label follow-up. These findings require replication to definitively determine clinical utility of this treatment. Trial Registration clinicaltrials.gov Identifier: NCT00720538 As many as 1.2 million people in Europe and more than half a million in the United States are estimated to have Crohn disease. Its incidence is increasing globally,1- 3 and its prevalence is particularly high in North America and Europe (319 to 322 per 100 000 persons).2 About 25% of people with Crohn disease develop symptoms as children, and these cases are generally more severe than adult-onset cases. Resistance or intolerance to therapy is common in children with Crohn disease, with up to approximately 18% of cases requiring surgery within 5 years from disease onset. If not adequately treated, children with Crohn disease may have permanent impairments (eg, growth failure, osteoporosis, delayed sexual development, psychological disorders, failure to achieve full educational and career potential).4- 8 Few randomized trials have evaluated the efficacy and safety of second- and third-line drugs (ie, after failure of steroids or enteral nutrition) in children with Crohn disease.9- 13 Thalidomide is a small molecule with anti�tumor necrosis factor ?, immunomodulatory, and antiangiogenic properties.14,15 It has been used since the 1960s to treat patients with erythema nodosum leprosum (an immunologic complication of leprosy) and, more recently, several other inflammatory diseases of the skin and mucous membranes (aphthous stomatitis, Behcet syndrome, mouth and esophageal ulcers in human immunodeficiency virus, mucocutaneous graft-vs-host disease, and cutaneous manifestations of systemic lupus erythematosus).14,15 Observational studies on thalidomide in patients with Crohn disease have reported encouraging results, with remission rates ranging from 40% to 70%.14,15 We evaluated the efficacy and adverse effects of thalidomide in inducing clinical remission in children and adolescents with refractory Crohn disease in a multicenter, double-blind, placebo-controlled, randomized controlled trial.
Databáze: OpenAIRE
Externí odkaz: